Antibody Drugs Market Size Estimated to Reach $148.3 Billion by 2027

Antibody Drugs Market | IndustryARC
The soaring application of protein-based therapies and medications termed monoclonal antibodies in the treatment of incessant ailments is set to drive the Antibody Drugs Market

Antibody Drugs Market size is estimated to reach $148.3 billion by 2027, growing at a CAGR of 6.4% during the forecast period 2022-2027. Antibody indicates a class of protective immunoglobulin generated owing to the incitement of antigens like pathogenic bacteria and viruses and can fasten particularly to antigens. Antibody drugs which include antibody substances are made by antibody engineering technology on the basis of cell and gene engineering technology. Adcetris® is a CD30-directed Antibody Drug conjugate (ADC); meaning that it includes a targeted therapy monoclonal antibody and an antineoplastic (chemotherapy) agent. Adcetris® Is utilized for the treatment of mature grown-up patients with formerly untreated stage III or IV classical Hodgkin lymphoma (cHL) in integration with chemotherapy. Immunotherapy is a kind of cancer treatment that increases the natural defenses of the body to combat cancer. There are numerous kinds of immunotherapy including monoclonal antibodies and tumor-agnostic treatments like checkpoint inhibitors, oncolytic virus therapy, T-cell therapy, and cancer vaccines. Multidrug resistance in Escherichia coli has evolved into a concern that is increasingly noticed in humans but also in veterinary medicine globally. Escherichia coli is intrinsically vulnerable to almost all clinically appropriate antimicrobial agents. However, this bacterial species has a great capability to amass resistance genes, mostly by way of horizontal gene transfer.

The soaring application of protein-based therapies and medications termed monoclonal antibodies in the treatment of incessant ailments is set to drive the Antibody Drugs Market. The rise of targeted therapy and combinational therapy which may apply targeted therapy and immunotherapy are set to propel the growth of the Antibody Drugs Market during the forecast period 2022-2027. This represents the Antibody Drugs Industry Outlook.

Antibody Drugs Market Segment Analysis – By Product Type

The Antibody Drugs Market based on product type can be further segmented into Monoclonal Antibodies, Antibody-Drug Conjugates, and Polyclonal Antibodies. The Monoclonal Antibodies Segment held the largest market share in 2021. This growth is owing to the increasing application of monoclonal antibodies as immunotherapy in the treatment of ailments like cancer. Monoclonal antibodies serve as immunotherapy owing to their ability to make the immune system respond better to permit the body to detect and attack cancer cells more efficiently. The surging application of monoclonal antibody therapy for COVID-19 is further propelling the growth of the Monoclonal Antibodies segment.

Furthermore, the Antibody-Drug Conjugates segment is estimated to grow with the fastest CAGR of 6.9% during the forecast period 2022-2027 owing to the soaring application of antibody-drug conjugates as immunotherapy depending on the capability of monoclonal antibodies (mAbs) to aim at specific tumor-associated antigens (TAAs) and to be utilized as carriers to particularly transfer cytotoxic warheads into corresponding tumor cells.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=15697

Report Price: $ 4500 (Single User License)

Antibody Drugs Market Segment Analysis – By Application

The Antibody Drugs Market based on the application can be further segmented into Central Nervous System Ailments, Cancer, Autoimmune Ailments, Cardiovascular Disease, and Others. The Cancer Segment held the largest market share in 2021. This growth is owing to the increasing predominance of cancer worldwide resulting in the greater application of immunotherapy involving monoclonal antibodies. Monoclonal antibodies are a particular kind of antibody, developed in the laboratory to detect and destroy a specific target like cancer. The surging application of monoclonal antibodies for the treatment of colorectal cancer and their anticipated reduced side-effects are further propelling the growth of this segment.

Furthermore, the Cardiovascular Disease segment is estimated to grow with the fastest CAGR of 7.3% during the forecast period 2022-2027 owing to the surging application of antibody-based therapeutics including monoclonal antibodies against Proprotein convertase subtilisin/Kexin type 9 (PCSK9) (alirocumab, evolocumab) as immunotherapy treatment for the occurrence of cardiovascular disease.

Antibody Drugs Market Segment Analysis – By Geography

The Antibody Drugs Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Antibody Drugs Market) held the largest share with 36% of the overall market in 2021. The growth of this region is owing to the strong healthcare infrastructure in the region. The increasing essentiality of attending to the urgent unmet requirement in the treatment of cancer requiring the application of immunotherapy and immunological ailments like rheumatoid is further driving the growth of the Antibody Drugs Market in this region. The higher affordability of consumers and the soaring rate of acceptance of novel technology are further propelling the growth of the Antibody Drugs Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing predominance of infectious ailments in countries like India and China in the Asia-Pacific region. The enormous patient base and the proliferating application of immunotherapy involving monoclonal antibodies in the treatment of cancer are further fuelling the progress of the Antibody Drugs Market in the Asia-Pacific region.

Antibody Drugs Market Drivers

Surging Applications Of Adcetris Are Projected To Drive The Growth Of Antibody Drugs Market:

ADCETRIS® (brentuximab vedotin) for injection is designated for the treatment of mature grown-up patients with formerly untreated Stage III/IV classical Hodgkin lymphoma (cHL) in integration with doxorubicin, vinblastine, and dacarbazine (AVD). ADCETRIS+AVD presented excellent efficacy vs ABVD, which is a chemotherapy regimen utilized in the first-line treatment of Hodgkin lymphoma. ADCETRIS® (brentuximab vedotin) for injection is designated for the treatment of mature grown-up patients with cHL at soaring hazard of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. It is also designated for cases of relapsed cHL, formerly untreated sALCL or additional CD30-expressing PTCL, relapsed sALCL, and relapsed pcALCL or CD30-expressing MF. The surging applications of Adcetris are therefore fuelling the growth of the Antibody Drugs Market during the forecast period 2022-2027.

Soaring Applications Of Immunotherapy Are Expected To Boost The Demand Of Antibody Drugs Market:

Targeted therapies are planned to attack cancer cells with the assistance of antibodies and chemotherapy. They are based on the concept that cancer cells have abnormal versions of some proteins, termed receptors, that are existing in normal cells but not in cancer cells. These targeted therapies can utilize antibodies against these receptors. Immunotherapy is a kind of treatment that utilizes the immune system to combat cancer. It is also termed biotherapy. This kind of treatment can be either utilized alone or in integration with additional therapies. Immunotherapy is a kind of biological therapy. Biological therapy is a kind of treatment that utilizes substances prepared from living organisms to treat cancer. Monoclonal antibodies, which are immune system proteins developed in the laboratory that are planned to fasten to particular targets on cancer cells. Certain monoclonal antibodies mark cancer cells so that they will be better observed and destroyed by the immune system. These kinds of monoclonal antibodies are a kind of immunotherapy. Monoclonal antibodies may also be termed therapeutic antibodies. The soaring applications of immunotherapy involving monoclonal antibodies are driving the growth of the Antibody Drugs Market during the forecast period 2022-2027.

Direct Purchase link @ https://www.industryarc.com/purchasereport.php?id=15697

Antibody Drugs Market Challenges

Functional Disadvantages Of Therapeutic Antibodies Are Hampering The Growth Of The Antibody Drugs Market:

Certain functional disadvantages of therapeutic antibodies have been noticed like insufficient pharmacokinetics and tissue accessibility and impaired interactions with the immune system and these deficiencies indicate areas where more research is required. Monoclonal antibodies after being initially developed, encountered severe issues when utilized as therapeutics. The first monoclonal antibodies were murine molecules and were identified as foreign when injected into patients, resulting in their removal by the patient’s immune system. Moreover, in order to be efficient, antibodies are frequently required to interact with some elements of the immune system like receptors displayed on effector cells or the complement cascade. Owing to their murine nature, these early antibodies did not interact appropriately with constituents of the human immune system and their biological efficacy was seriously limited. These kinds of issues are thus hampering the growth of the Antibody Drugs Market.

Antibody Drugs Market – Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antibody Drugs Market. Key companies of this market are:

Abbott Laboratories
GlaxoSmithKline plc
Sanofi S.A.
Novartis AG
Eli Lilly & Company
Femta Pharmaceuticals
La Jolla Pharmaceuticals
Spectrum Pharmaceuticals
Alexion Pharmaceuticals
Hoffman-La Roche

Recent Developments

In December 2021, Roche declared the introduction of the AVENIO Edge System, a core constituent of Roche’s strategy to progress sequencing technologies. Constructed on best-in-class foundational capabilities to transfer a completely-automatized, combined sequencing solution. The AVENIO Edge System is a pre-analytical platform for sequencing library preparation, target enrichment, and quantification steps that transfer combined, end-to-end regulation with trustworthy, constant high-quality results.

In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory tool, in nations accepting the CE mark. Testing is one of the earliest lines of defense to safeguard a patient’s general well-being and is very important in expeditiously guiding their treatment. The cobas 5800 System assists in attending to challenges that the laboratories are encountering from a boost in inpatient testing, reimbursement complications, and the requirement for a more distinct testing menu while offering meaningful and timely outcomes.

In January 2021, Roche declared the CE-IVD introduction of its automatized digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath Dual ISH image analysis for breast cancer to assist in deciding the most excellent treatment strategy for every patient. The image analysis algorithms utilize artificial intelligence to back pathologists in making quicker, more precise patient diagnoses in breast cancer. A mutation in the HER2 gene, which happens in as many as 20 percent of the 2.1 million cases of breast cancer diagnosed worldwide every year, is accountable for intrusive development in certain patients.

Key Takeaways

Geographically, North America Antibody Drugs Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging application of antibody drugs and immunotherapy in the North American region.

Antibody Drugs Market growth is being driven by the soaring accessibility of numerous antibody drugs developed as a result of progress in the field of biotechnology, the reduced side-effects associated with them, and the high efficiency in healing some ailments that were formerly regarded untreatable in conjunction with the surging application of monoclonal antibodies as part of immunotherapy. However, monoclonal antibodies are very high-priced owing to their heightened complexity and the soaring cost to manufacture them in comparison with other kinds of medications and this is one of the major factors hampering the growth of the Antibody Drugs Market.

Antibody Drugs Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Antibody Drugs Market report.

Related Reports:-

Antibody Testing Market

https://www.industryarc.com/Report/19287/antibody-testing-market.html

For more Lifesciences and Healthcare Market reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

Media Contact
Company Name: IndustryARC
Contact Person: Mr. Venkat Reddy
Email: Send Email
Phone: (+1) 970-236-3677
Address:Madhapur
City: Hyderabad
Country: India
Website: https://www.industryarc.com/